ADRIANA

ADRIANA
Clinical data
Routes of
administration		Oral
Drug classSelective α2B-adrenergic receptor antagonist; Analgesic
ATC code
  • None
Identifiers
  • (1Z)-1-(3-ethyl-5-fluoro-1,3-benzothiazol-2-ylidene)propan-2-one
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H12FNOS
Molar mass237.29 g·mol−1
3D model (JSmol)
  • CCN\1C2=C(C=CC(=C2)F)S/C1=C\C(=O)C
  • InChI=1S/C12H12FNOS/c1-3-14-10-7-9(13)4-5-11(10)16-12(14)6-8(2)15/h4-7H,3H2,1-2H3/b12-6-
  • Key:KZNPXNKNIBBYSS-SDQBBNPISA-N

ADRIANA is a selective α2B-adrenergic receptor antagonist. It is described as highly selective over the α2A- and α2C-adrenergic receptors. The drug stimulates norepinephrine release in the spinal dorsal horn and has potent analgesic effects in rodents and non-human primates. It is orally active. ADRIANA was first described in the scientific literature by Masayasu Toyomoto and colleagues in 2025. It is said to be the first selective α2B-adrenergic receptor antagonist to have been developed.

See also

References

  1. 1 2 3 4 5 6 7 Toyomoto M, Kurihara T, Nakagawa T, Inoue A, Kimura R, Kii I, et al. (August 2025). "Discovery and development of an oral analgesic targeting the α2B adrenoceptor". Proceedings of the National Academy of Sciences of the United States of America. 122 (32) e2500006122. Bibcode:2025PNAS..12200006T. doi:10.1073/pnas.2500006122. PMC 12358833. PMID 40773228.